Revised: 26 April 2021

Nocturnal dipping of heart rate and blood pressure in people with HIV in Tanzania

Cody Nolan MD^{1,2} | Karl Reis BA^{1,3,4} | Salama Fadhil BA^{3,4} | Anthony Etyang MD⁵ | Chiomah Ezeomah MS^{1,6} | Justin R. Kingery MD, PhD^{1,3,4,7} | Bernard Desderius MD⁴ | Myung-Hee Lee PhD¹ | Saidi Kapiga MD, ScD³ | Robert N. Peck MD, PhD^{1,3,4}

People with HIV (PWH) have a >2-fold greater risk for development of cardiovascular

disease (CVD), which may be associated with abnormalities in 24-h ambulatory blood

pressure measurement (ABPM) profile. We conducted a nested case-control study

of ABPM in 137 PWH and HIV-uninfected controls with normal and high clinic blood

pressure (BP) in Tanzania. Nocturnal non-dipping of heart rate (HR) was significantly

more common among PWH than HIV-uninfected controls (p = .01). Nocturnal non-

dipping of BP was significantly more common in PWH with normal clinic BP (p = .048).

Clinical correlates of nocturnal non-dipping were similar in PWH and HIV-uninfected

adults and included higher BMI, higher CD4⁺ cell count, and high C-reactive protein

for HR and markers of renal disease for BP. In conclusion, nocturnal non-dipping of

both BP and HR was more common in PWH but further research is needed to deter-

Abstract

¹Center for Global Health, Weill Cornell Medicine, New York, NY, USA

²Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA

³Mwanza Interventional Trials Unit (MITU), Mwanza, Tanzania

⁴Weill Bugando School of Medicine, Mwanza, Tanzania

⁵KEMRI-Wellcome Trust Research Program, Kilifi, Kenya

⁶Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA

⁷Division of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA

Correspondence

Robert N. Peck, Center for Global Health, Weill Cornell Medicine, 402 East 67th Street, New York, NY, USA. Email: rnp2002@med.cornell.edu

Funding information

This work was supported by a grant from the NIH-Fogarty International Center (K01TW010281)

1 | INTRODUCTION

Ambulatory blood pressure monitoring (ABPM)—the measurement of blood pressure (BP) over a 24-h period—is the reference standard for BP measurement.¹ ABPM results predict cardiovascular disease (CVD) events and mortality more accurately than clinic BP measurements.² Additionally, ABPM allows for the identification of high-risk phenotypes—including nocturnal non-dipping of BP and heart rate (HR)—which cannot be diagnosed in the clinic. People with HIV (PWH) have a twofold to fourfold higher incidence of CVD.^{3,4} This increased risk may be partly attributable to abnormalities in nocturnal BP and HR.⁵ We do not yet know whether these ABPM abnormalities observed in PWH differ by clinic BP status.

Therefore, we conducted a nested case-control study comparing ABPM in PWH with normal and high clinic BP and HIVuninfected controls in Tanzania. Objectives of this research were as follows: 1) to compare nocturnal non-dipping of BP and HR between PWH and HIV-uninfected controls and 2) to determine

Cody Nolan and Karl Reis have contributed equally to the work.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC

mine causes and consequences of this difference.

correlates of nocturnal non-dipping of BP and HR in PWH and HIV-uninfected controls.

2 | METHODS

2.1 | Study cohort

This nested case-control study was conducted within a welldescribed prospective cohort⁶ of PWH attending an outpatient HIV clinic in Tanzania and HIV-uninfected controls.

2.2 | Study population

Cohort inclusion criteria include age 18-65 years, Tanzanian citizenship, and residing in Mwanza City. Exclusion criteria for both groups include previous history of CVD and a medical condition with a prognosis of <12 months.

2.3 | Study location

All study activities were performed in the outpatient HIV clinic at Bugando Medical Centre, in Mwanza, Tanzania.

2.4 | Study procedures

Study procedures have been described in detail previously.⁶ At each study visit, a standardized questionnaire and physical examination were administered. Automated BP was measured using an OMRON HBP-1300 (OMRON Healthcare) professional BP monitor. High clinic BP was defined as BP measurements (≥140/90 mmHg) on at least two consecutive visits according to the International Society of Hypertension (ISH) threshold.⁷

2.5 | Ambulatory blood pressure monitoring study design

From February 2018 to June 2018, we performed ABPM on 50 consecutive cohort participants attending scheduled research clinic appointments with normal clinic BP. We also performed ABPM on all participants with high clinic BP.

2.6 | Ambulatory blood pressure measurement

Ambulatory blood pressure monitoring was performed using the validated SunTech Medical[®] Oscar 2 machine, programmed via the AccuWin Pro 4 software to measure BP for 24 h at an interval of 15 min. Initial readings were confirmed in-clinic. Participants

were instructed to return to the clinic after 24 h. The following day self-reported sleep and wake times were recorded. All participants identified as hypertensive were referred to a physician and offered free hypertension treatment according to the Tanzanian guidelines.^{8,9} All ABPM met European Society of Hypertension (ESH) quality control guidelines for ABPM, which require >20 daytime and >7 nighttime measurements, and ≥70% valid measurements of expected measurements. Nocturnal non-dipping of HR/ BP was defined as an asleep HR/BP reduction of ≥10% of awake values.¹⁰

2.7 | Laboratory procedures

CD4⁺ T-cell count was measured using an automated BD FACS Calibur Machine (BD Biosciences) for PWH. Serum creatinine level was measured using the A25 Analyzer (Biosystems), calibrated by the creatinine Jaffé 2 method. An estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Equation.¹¹ Urine albumin and creatinine were measured with the Siemens DCA Vantage Analyzer (Siemens Healthcare). High-sensitivity serum C-reactive protein (hsCRP) concentration was measured using R&D Systems Quantikine ELISA (R&D Systems). hsCRP measurements were classified according to cardiovascular risk,¹² with hsCRP >3 mg/L representing high risk and hrCRP \leq 3 mg/L representing low/intermediate risk.

2.8 | Statistical methods

Data were double entered into OpenClinica (OpenClinica LLC). Baseline participant characteristics were summarized using median and interquartile range for continuous variables and frequency and percent for categorical variables. For categorical variables, chi-squared tests or Fisher's exact tests, as appropriate, were performed to evaluate the association between HIV status and BP/HR dipping status. Multivariate logistic regression analyses adjusted for clinic systolic blood pressure (SBP) were used to evaluate factors associated with nocturnal non-dipping of BP/HR. All analysis was conducted using Stata version 15.1 (STATACorp LLC).

2.9 | Ethics

The study was carried out in accordance with Good Clinical Practice and the Declaration of Helsinki. The study and consent forms were approved by the Weill Cornell Medicine (1506016328), the Tanzanian National Institute of Medical Research (NIMR/HQ/R.8c/Vol.1/1399), and Bugando Medical Centre (CREC/074/2015). All participants provided written informed consent.

3 | RESULTS

3.1 | Study population and characteristics

The baseline characteristics of all study participants are displayed in Table S1. Of the 137 participants selected, 50 had normal clinic BP (25 PWH and 25 HIV-uninfected) and 87 had high clinic BP (31 PWH and 56 HIV-uninfected). None of the participants had started anti-hypertensive medication at the time of ABPM measurement. All of the PWH were on ART. Mean duration of ART use was 1.46 years and ranged from 0 to 3.15 years. PWH and HIV-uninfected controls were similar in age, sex distribution, and BMI (Table S1). Analysis of the associations between HIV infection and ABPM results are in Table S2.

3.2 | Nocturnal non-dipping of BP/HR in all participants

Overall, PWH had a higher prevalence of nocturnal non-dipping of HR (39.3% [22/56] in PWH vs. 19.8% [16/81] in HIV-uninfected controls, p = .01) than HIV-uninfected controls. Nocturnal non-dipping

of BP was more common in PWH but this did not reach statistical significance (64.2% [36/56] in PWH vs. 53.1% [43/81] in HIV-uninfected controls, p = .19).

3.3 | Nocturnal non-dipping of BP/HR in participants with normal versus high clinic BP

Prevalence of nocturnal non-dipping of HR/BP stratified by HIV status and clinic BP is displayed in Figure 1 and Table S3. Among participants with normal clinic BP, PWH had a higher prevalence of nocturnal non-dipping of BP (64.0% [16/25] in PWH vs. 36.0% (9/25) in HIV-uninfected controls, p = .048). Among participants with high clinic BP, PWH had a higher prevalence of nocturnal non-dipping of HR (41.9% [13/31] in PWH vs. 21.4% [12/56] in HIV-uninfected controls, p = .043) than HIV-uninfected controls.

3.4 | Correlates of non-dipping

Factors associated with nocturnal non-dipping of HR and BP independent of clinic SBP were similar in PWH and HIV-uninfected



FIGURE 1 Nocturnal non-dipping of heart rate (HR) and blood pressure (BP) among people with HIV (PWH) and HIV-uninfected control participants stratified by clinic BP. Panel A: Prevalence of nocturnal non-dipping of HR by HIV status. Panel B: Prevalence of nocturnal non-dipping of BP by HIV status TABLE 1 Correlates of nocturnal non-dipping of blood pressure (BP)/heart rate (HR) in people with HIV (PWH), HIVuninfected controls, and all participants in multivariate logistic regression models adjusted for clinic systolic blood pressure

	All participants (n = 137)	PWH (n = 56)	HIV-uninfected (n = 81)
Nocturnal non-dipping of HR			
BMI	1.10 [1.02-1.18]*	1.08 [0.97-1.20]	1.14 [1.01-1.28]*
High hsCRP	2.32 [1.06-5.11]*	1.86 [0.60-5.70]	1.88 [0.56-6.34]
CD4 ⁺ T-cell count*	1.08 [0.97-1.21]	1.19 [1.00-1.42]*	1.14 [0.95-1.38]
Nocturnal non-dipping of BP			
eGFR < 60 ml/min/1.73m ²	4.48 [1.18-16.99]*	_ ^a	3.45 [0.83-14.3]
ACR ≥ 30 mg/g	3.96 [1.05-14.86]*	6.84 [0.71-65.75]	2.36 [0.43-13.13]

^aAll PWH with eGFR \ge 60 ml/min/1.73m² had nocturnal non-dipping of BP. *p < .05.

adults and are displayed in Table 1. Nocturnal non-dipping of HR was associated with higher BMI (aOR 1.10, 95% CI 1.02-1.18, p = .012), elevated hsCRP (aOR 2.32, 95% CI 1.05-5.11, p = .036), and CD4⁺ T-cell count per 100 cells/mm³ among PWH (aOR 1.19, 95% 1.00-1.42, p = 048). Nocturnal non-dipping of BP was associated with eGFR <60 ml/min/1.73m² (aOR 4.48, 95% CI 1.18-16.99, p = .027) and ACR ≥30 mg/g (aOR 3.96, 95% CI 1.05-14.86, p = .042).

4 | DISCUSSION

In this study of ABPM in Tanzania, we report that PWH have a higher prevalence of nocturnal non-dipping of both HR and BP than HIVuninfected participants. Overall, PWH were twice as likely (40% vs. 20%) to have nocturnal non-dipping of HR. In addition, PWH with normal clinic BP were twice as likely to have nocturnal non-dipping of BP (64% vs. 36%). Correlates of nocturnal non-dipping were similar in PWH and HIV-uninfected adults: HR non-dipping was associated with higher BMI, higher CD4+ cell count, and high hsCRP, and BP non-dipping was associated with both albuminuria and reduced eGFR.

Nocturnal non-dipping of HR was twice as common in PWH as in HIV-uninfected controls, regardless of BP status (40% vs. 20%). To the best of our knowledge, we are the first to report this higher rate of nocturnal non-dipping of HR in PWH. Emerging data indicate that nocturnal non-dipping of HR may independently predict CVD events and mortality in the general population.¹³ Nocturnal nondipping of HR was independently associated with higher hsCRP, indicating that non-dipping of HR in PWH could be related to chronic vascular inflammation. Nocturnal non-dipping of HR might partly explain the known association between elevated CRP and CVD and could provide a target for intervention.

Two-thirds of PWH and half of HIV-uninfected participants exhibited nocturnal non-dipping of BP. This difference was particularly pronounced among participants with normal clinic BP, where two-thirds of PWH and just one-third of HIV-uninfected controls had nocturnal non-dipping of BP. In the general population, this "normotensive non-dipper" phenotype has been associated with higher rates of CVD events independent of daytime BP, but this phenotype not been studied in PWH.¹⁴ Previous studies of nocturnal non-dipping of BP in PWH have consistently shown higher rates of nocturnal non-dipping of BP compared with HIV-uninfected adults, but have not investigated whether this difference varied by clinic BP status.⁵ Normotensive nocturnal non-dipping of BP deserves further investigation as possible new targets for CVD prevention in PWH.

Our study has limitations, including the small sample size and cross-sectional study design. In addition, HIV viral load was not performed at our clinic at the time of the study due to a national stockout of reagent. Lastly, due to the manual labor required daily in Tanzania, many participants had 1–2 h per day when they did not meet the final ESH quality control criteria of \geq 2 valid measurements per daytime hour and \geq 1 valid measurement per nighttime hour. However, studies indicate that ABPM with as few as eight daytime readings and four nighttime readings likely still retain diagnostic and predictive accuracy.¹⁵

In conclusion, PWH had a higher prevalence of nocturnal nondipping of BP and HR. Future research should determine the causes and consequences of nocturnal non-dipping of BP and HR in PWH to determine if non-dipping could be a novel target for intervention to prevent CVD in PWH.

ACKNOWLEDGEMENTS

We would like to acknowledge all of our participants, as well as our colleagues at Bugando Medical Centre and the Mwanza Intervention Trials Unit who lent invaluable support to this research.

CONFLICT OF INTEREST

The authors report no conflicts of interest.

AUTHOR CONTRIBUTIONS

CN contributed to study conception, design, data collection, and revised manuscript for important intellectual content. KR contributed to data collection, data analysis, data interpretation, manuscript preparation, and revised manuscript for important intellectual content. SF contributed to data collection, data analysis, and revised manuscript for important intellectual content. AE contributed to

1455

<u>¹⁴⁵⁶</u>| ₩ILEY

data analysis, data interpretation, and revised manuscript for important intellectual content. CE contributed to data analysis, data interpretation, manuscript preparation, and revised manuscript for important intellectual content. JK contributed to study conception, study design, data collection, manuscript preparation, and revised manuscript for important intellectual content. CM contributed to study conception, study design, manuscript preparation, and revised manuscript for important intellectual content. ML contributed to study design, data analysis, data interpretation, manuscript preparation, and revised manuscript for important intellectual content. SK contributed to study conception, study design, data interpretation, manuscript preparation, and revised manuscript for important intellectual content. RP contributed to study conception, study design, data collection, data analysis, data interpretation, manuscript preparation, and revised manuscript for important intellectual content. RP contributed to study conception, study design, data collection, data analysis, data interpretation, manuscript preparation, and revised manuscript for important intel-

ORCID

Karl Reis 🕩 https://orcid.org/0000-0002-9509-4526

REFERENCES

- O'Brien E, Parati G, Stergiou G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31(9):1731-1768. https://doi.org/10.1097/ HJH.0b013e328363e964
- Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368-2374.
- Barnes RP, Lacson JCA, Bahrami H. HIV infection and risk of cardiovascular diseases beyond coronary artery disease. *Curr Atheroscler Rep.* 2017;19:20.
- Freiberg MS, Chang C-CH, Skanderson M, et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the veterans aging cohort study. JAMA Cardiol. 2017;2:536-546.
- Kent ST, Bromfield SG, Burkholder GA, et al. Ambulatory blood pressure monitoring in individuals with HIV: a systematic review and meta-analysis. *PLoS One*. 2016;11:e0148920.
- Reis KG, Desderius B, Kingery J, et al. Blood pressure, T cells, and mortality in people with HIV in Tanzania during the first 2 years of antiretroviral therapy. J Clin Hypertens. 2020;22(9):1554-1562. https://doi.org/10.1111/jch.13975

- Unger T, Borghi C, Charchar F, et al. 2020 International society of hypertension global hypertension practice guidelines. *Hypertension*. 2020;75:1334-1357.
- Tanzania Ministry of Health. Standard Treatment Guidelines & National Essential Medications List: Tanzania Mainland. 2017. http:// www.tzdpg.or.tz/dpg-website/dpg-tanzania.html
- Mzombwe M, Desderius B, Kapiga S, Smart L, Peck R. The ethical imperative to treat NCDs during research in Africa. *Lancet Glob Heal*. 2019;7:e406-e407.
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39:3021-3104.
- Wyatt CM, Schwartz GJ, Owino Ong'or W, et al. Estimating kidney function in HIV-infected adults in Kenya: comparison to a direct measure of glomerular filtration rate by iohexol clearance. *PLoS One.* 2013;8:e69601.
- Roberts WL. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: laboratory tests available to assess inflammationperformance and standardization: a background paper. *Circulation*. 2004;110:E572-E576.
- 13. Cuspidi C, Facchetti R, Bombelli M, et al. Night-time heart rate nondipping: clinical and prognostic significance in the general population. *J Hypertens*. 2018;36:1311-1317.
- Hermida RC, Ayala DE, Mojón A, Fernández JR. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level-the "Normotensive non-dipper" paradox. Chronobiol Int. 2013;30:87-98.
- Yang W-Y, Thijs L, Zhang Z-Y, et al. Evidence-based proposal for the number of ambulatory readings required for assessing blood pressure level in research settings: an analysis of the IDACO database. *Blood Press.* 2018;27:341-350.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Nolan C, Reis K, Fadhil S, et al. Nocturnal dipping of heart rate and blood pressure in people with HIV in Tanzania. *J Clin Hypertens*. 2021;23:1452–1456. https://doi.org/10.1111/jch.14300